$BMRN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in BIOMARIN PHARMACEUTICAL INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in BIOMARIN PHARMACEUTICAL INC. Get notifications about new insider transactions in BIOMARIN PHARMACEUTICAL INC for free.
Page: < prev 1 ... 3 4 5 6 7 8 9 10 11 ... 34 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Option Exercise | A | 87.42 | 36,280 | 3,171,598 | 36,820 | |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Grant | A | 0.00 | 11,220 | 0 | 84,949 | 73.7 K to 84.9 K (+15.22 %) |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | A | 87.42 | 144,050 | 12,592,851 | 144,050 | |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Grant | A | 0.00 | 44,520 | 0 | 235,194 | 190.7 K to 235.2 K (+23.35 %) |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Option Exercise | A | 87.42 | 7,740 | 676,631 | 7,740 | |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Grant | A | 0.00 | 4,790 | 0 | 18,080 | 13.3 K to 18.1 K (+36.04 %) |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | A | 87.42 | 64,030 | 5,597,503 | 64,030 | |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Grant | A | 0.00 | 19,790 | 0 | 140,192 | 120.4 K to 140.2 K (+16.44 %) |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | A | 87.42 | 39,480 | 3,451,342 | 39,480 | |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 12,200 | 0 | 55,422 | 43.2 K to 55.4 K (+28.23 %) |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Option Exercise | A | 87.42 | 39,480 | 3,451,342 | 39,480 | |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 0.00 | 12,200 | 0 | 26,671 | 14.5 K to 26.7 K (+84.31 %) |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Option Exercise | A | 87.42 | 38,420 | 3,358,676 | 38,420 | |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Grant | A | 0.00 | 11,870 | 0 | 147,491 | 135.6 K to 147.5 K (+8.75 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 92.50 | 3,288 | 304,140 | 43,222 | 46.5 K to 43.2 K (-7.07 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 92.50 | 5,116 | 473,230 | 120,402 | 125.5 K to 120.4 K (-4.08 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Payment of Exercise | F | 92.50 | 3,289 | 304,233 | 135,621 | 138.9 K to 135.6 K (-2.37 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 90.96 | 376 | 34,201 | 13,290 | 13.7 K to 13.3 K (-2.75 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 92.50 | 336 | 31,080 | 13,666 | 14 K to 13.7 K (-2.40 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 91.96 | 2,238 | 205,806 | 73,729 | 76 K to 73.7 K (-2.95 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 92.50 | 2,995 | 277,038 | 75,967 | 79 K to 76 K (-3.79 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 91.96 | 1,989 | 182,908 | 14,471 | 16.5 K to 14.5 K (-12.08 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 92.50 | 4,301 | 397,843 | 16,460 | 20.8 K to 16.5 K (-20.72 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 5,000 | 86,650 | 57,423 | |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 5,000 | 86,650 | 62,423 | |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 91.96 | 5,000 | 459,800 | 190,674 | 195.7 K to 190.7 K (-2.56 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 71.33 | 5,000 | 356,650 | 195,674 | 190.7 K to 195.7 K (+2.62 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 92.50 | 15,690 | 1,451,325 | 190,674 | 206.4 K to 190.7 K (-7.60 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 91.42 | 5,000 | 457,100 | 206,364 | 211.4 K to 206.4 K (-2.37 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 5,000 | 86,650 | 211,364 | 206.4 K to 211.4 K (+2.42 %) |
Mar 15 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 5,000 | 86,650 | 67,423 | |
Mar 15 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 92.68 | 5,000 | 463,400 | 206,364 | 211.4 K to 206.4 K (-2.37 %) |
Mar 15 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 5,000 | 86,650 | 211,364 | 206.4 K to 211.4 K (+2.42 %) |
Mar 13 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 5,000 | 86,650 | 72,423 | |
Mar 13 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 6,000 | 103,980 | 77,423 | |
Mar 13 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 91.09 | 5,000 | 455,450 | 206,364 | 211.4 K to 206.4 K (-2.37 %) |
Mar 13 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 5,000 | 86,650 | 211,364 | 206.4 K to 211.4 K (+2.42 %) |
Mar 13 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 90.18 | 6,000 | 541,080 | 206,364 | 212.4 K to 206.4 K (-2.83 %) |
Mar 13 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 6,000 | 103,980 | 212,364 | 206.4 K to 212.4 K (+2.91 %) |
Mar 08 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 90.56 | 5,000 | 452,800 | 46,510 | 51.5 K to 46.5 K (-9.71 %) |
Mar 08 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 93.32 | 2,303 | 214,916 | 20,761 | 23.1 K to 20.8 K (-9.99 %) |
Mar 08 2017 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 93.32 | 1,498 | 139,793 | 78,962 | 80.5 K to 79 K (-1.86 %) |
Mar 07 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 93.95 | 1,749 | 164,319 | 51,510 | 53.3 K to 51.5 K (-3.28 %) |
Mar 07 2017 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Payment of Exercise | F | 93.95 | 1,749 | 164,319 | 138,910 | 140.7 K to 138.9 K (-1.24 %) |
Mar 07 2017 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 93.95 | 1,596 | 149,944 | 80,460 | 82.1 K to 80.5 K (-1.95 %) |
Mar 07 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 93.95 | 2,283 | 214,488 | 23,064 | 25.3 K to 23.1 K (-9.01 %) |
Mar 07 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 93.95 | 8,989 | 844,517 | 206,364 | 215.4 K to 206.4 K (-4.17 %) |
Mar 07 2017 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 93.95 | 2,924 | 274,710 | 125,518 | 128.4 K to 125.5 K (-2.28 %) |
Jan 27 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 5,000 | 86,650 | 83,423 | |
Jan 27 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 5,000 | 86,650 | 88,423 | |
Jan 27 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 84.00 | 5,000 | 420,000 | 170,682 | 175.7 K to 170.7 K (-2.85 %) |
Jan 27 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 5,000 | 86,650 | 175,682 | 170.7 K to 175.7 K (+2.93 %) |
Jan 27 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 84.44 | 5,000 | 422,200 | 170,682 | 175.7 K to 170.7 K (-2.85 %) |
Jan 27 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 5,000 | 86,650 | 175,682 | 170.7 K to 175.7 K (+2.93 %) |
Jan 12 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 4,000 | 69,320 | 93,423 | |
Jan 12 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 4,000 | 69,320 | 97,423 | |
Jan 12 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 89.84 | 4,000 | 359,360 | 170,682 | 174.7 K to 170.7 K (-2.29 %) |
Jan 12 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 4,000 | 69,320 | 174,682 | 170.7 K to 174.7 K (+2.34 %) |
Jan 12 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 91.31 | 4,000 | 365,240 | 170,682 | 174.7 K to 170.7 K (-2.29 %) |
Jan 12 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 4,000 | 69,320 | 174,682 | 170.7 K to 174.7 K (+2.34 %) |
Jan 10 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 4,000 | 69,320 | 101,423 | |
Jan 10 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 4,000 | 69,320 | 105,423 | |
Jan 10 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 89.79 | 4,000 | 359,160 | 170,682 | 174.7 K to 170.7 K (-2.29 %) |
Jan 10 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 4,000 | 69,320 | 174,682 | 170.7 K to 174.7 K (+2.34 %) |
Jan 10 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 87.19 | 4,000 | 348,760 | 170,682 | 174.7 K to 170.7 K (-2.29 %) |
Jan 10 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 4,000 | 69,320 | 174,682 | 170.7 K to 174.7 K (+2.34 %) |
Jan 10 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 90.00 | 5,000 | 450,000 | 18,100 | 23.1 K to 18.1 K (-21.65 %) |
Jan 03 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 4,000 | 69,320 | 109,423 | |
Jan 03 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 4,000 | 69,320 | 113,423 | |
Jan 03 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 83.35 | 4,000 | 333,400 | 170,682 | 174.7 K to 170.7 K (-2.29 %) |
Jan 03 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 4,000 | 69,320 | 174,682 | 170.7 K to 174.7 K (+2.34 %) |
Jan 03 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 83.84 | 4,000 | 335,360 | 170,682 | 174.7 K to 170.7 K (-2.29 %) |
Jan 03 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 4,000 | 69,320 | 174,682 | 170.7 K to 174.7 K (+2.34 %) |
Nov 29 2016 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | M | 26.49 | 15,000 | 397,350 | 35,225 | |
Nov 29 2016 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Sell | S | 87.40 | 15,000 | 1,310,988 | 113,878 | 128.9 K to 113.9 K (-11.64 %) |
Nov 29 2016 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Buy | M | 26.49 | 15,000 | 397,350 | 128,878 | 113.9 K to 128.9 K (+13.17 %) |
Nov 23 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 26.49 | 69,743 | 1,847,492 | 140,513 | |
Nov 23 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 26.49 | 69,744 | 1,847,519 | 210,256 | |
Nov 23 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 85.69 | 69,743 | 5,976,515 | 170,682 | 240.4 K to 170.7 K (-29.01 %) |
Nov 23 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 26.49 | 69,743 | 1,847,492 | 240,425 | 170.7 K to 240.4 K (+40.86 %) |
Nov 23 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 87.56 | 69,744 | 6,106,478 | 170,682 | 240.4 K to 170.7 K (-29.01 %) |
Nov 23 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 26.49 | 69,744 | 1,847,519 | 240,426 | 170.7 K to 240.4 K (+40.86 %) |
Nov 22 2016 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Option Exercise | M | 38.59 | 5,000 | 192,950 | 42,344 | |
Nov 22 2016 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 90.42 | 5,000 | 452,100 | 70,798 | 75.8 K to 70.8 K (-6.60 %) |
Nov 22 2016 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Buy | M | 38.59 | 5,000 | 192,950 | 75,798 | 70.8 K to 75.8 K (+7.06 %) |
Nov 22 2016 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Gift | G | 0.00 | 360 | 0 | 70,798 | 71.2 K to 70.8 K (-0.51 %) |
Nov 18 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.54 | 41,670 | 730,892 | 0 | |
Nov 18 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 90.97 | 41,670 | 3,790,795 | 323,368 | 365 K to 323.4 K (-11.42 %) |
Nov 18 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.54 | 41,670 | 730,892 | 365,038 | 323.4 K to 365 K (+12.89 %) |
Nov 14 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 90.61 | 20,000 | 1,812,206 | 23,100 | 43.1 K to 23.1 K (-46.40 %) |
Nov 14 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 68.44 | 156 | 10,677 | 43,100 | 42.9 K to 43.1 K (+0.36 %) |
Nov 14 2016 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Option Exercise | M | 17.33 | 7,500 | 129,975 | 7,500 | |
Nov 14 2016 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Sell | S | 95.00 | 7,500 | 712,500 | 13,860 | 21.4 K to 13.9 K (-35.11 %) |
Nov 14 2016 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Buy | M | 17.33 | 7,500 | 129,975 | 21,360 | 13.9 K to 21.4 K (+54.11 %) |
Nov 09 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 70,000 | 1,505,700 | 140,000 | |
Nov 09 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 21.51 | 70,000 | 1,505,700 | 210,000 | |
Nov 09 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 82.83 | 70,000 | 5,797,806 | 323,368 | 393.4 K to 323.4 K (-17.80 %) |
Nov 09 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 70,000 | 1,505,700 | 393,368 | 323.4 K to 393.4 K (+21.65 %) |
Nov 09 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 82.52 | 70,000 | 5,776,435 | 323,368 | 393.4 K to 323.4 K (-17.80 %) |
Nov 09 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 21.51 | 70,000 | 1,505,700 | 393,368 | 323.4 K to 393.4 K (+21.65 %) |
Oct 31 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 60,000 | 863,400 | 117,000 | |
Oct 31 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 60,000 | 863,400 | 177,000 | |
Oct 31 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 81.27 | 60,000 | 4,875,990 | 323,368 | 383.4 K to 323.4 K (-15.65 %) |
Oct 31 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 60,000 | 863,400 | 383,368 | 323.4 K to 383.4 K (+18.55 %) |
Oct 31 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 81.34 | 60,000 | 4,880,448 | 323,368 | 383.4 K to 323.4 K (-15.65 %) |
Oct 31 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 60,000 | 863,400 | 383,368 | 323.4 K to 383.4 K (+18.55 %) |
Oct 19 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.54 | 41,666 | 730,822 | 41,670 | |
Oct 19 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 84.39 | 41,666 | 3,516,227 | 323,368 | 365 K to 323.4 K (-11.41 %) |
Oct 19 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.54 | 41,666 | 730,822 | 365,034 | 323.4 K to 365 K (+12.89 %) |
Oct 17 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.86 | 11,000 | 196,460 | 11,000 | |
Oct 17 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 53,125 | 2,050,094 | 212,500 | |
Oct 17 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 86.89 | 11,000 | 955,814 | 323,368 | 334.4 K to 323.4 K (-3.29 %) |
Oct 17 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.86 | 11,000 | 196,460 | 334,368 | 323.4 K to 334.4 K (+3.40 %) |
Oct 17 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 86.98 | 53,125 | 4,620,563 | 323,368 | 376.5 K to 323.4 K (-14.11 %) |
Oct 17 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 53,125 | 2,050,094 | 376,493 | 323.4 K to 376.5 K (+16.43 %) |
Oct 17 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Gift | G | 0.00 | 200 | 0 | 377,484 | 377.7 K to 377.5 K (-0.05 %) |
Oct 17 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Gift | G | 0.00 | 500 | 0 | 377,684 | 378.2 K to 377.7 K (-0.13 %) |
Oct 17 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Gift | G | 0.00 | 400 | 0 | 378,184 | 378.6 K to 378.2 K (-0.11 %) |
Oct 04 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 53,125 | 2,050,094 | 265,625 | |
Oct 04 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 92.02 | 53,125 | 4,888,780 | 378,584 | 431.7 K to 378.6 K (-12.31 %) |
Oct 04 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 53,125 | 2,050,094 | 431,709 | 378.6 K to 431.7 K (+14.03 %) |
Oct 03 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 53,125 | 2,050,094 | 318,750 | |
Oct 03 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 93.65 | 53,125 | 4,974,901 | 378,584 | 431.7 K to 378.6 K (-12.31 %) |
Oct 03 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 53,125 | 2,050,094 | 431,709 | 378.6 K to 431.7 K (+14.03 %) |
Sep 29 2016 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 95.61 | 18,467 | 1,765,648 | 41,342 | 59.8 K to 41.3 K (-30.88 %) |
Sep 19 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.54 | 41,666 | 730,822 | 83,336 | |
Sep 19 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 53,125 | 2,050,094 | 371,875 | |
Sep 19 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 42,577 | 737,859 | 117,423 | |
Sep 19 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 95.97 | 41,666 | 3,998,561 | 378,584 | 420.3 K to 378.6 K (-9.91 %) |
Sep 19 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.54 | 41,666 | 730,822 | 420,250 | 378.6 K to 420.3 K (+11.01 %) |
Sep 19 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 95.25 | 53,125 | 5,060,039 | 378,584 | 431.7 K to 378.6 K (-12.31 %) |
Sep 19 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 53,125 | 2,050,094 | 431,709 | 378.6 K to 431.7 K (+14.03 %) |
Sep 19 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 94.85 | 42,577 | 4,038,360 | 378,584 | 421.2 K to 378.6 K (-10.11 %) |
Sep 19 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 42,577 | 737,859 | 421,161 | 378.6 K to 421.2 K (+11.25 %) |
Aug 30 2016 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | EVP, Chief Medical ... | Option Exercise | M | 26.49 | 15,000 | 397,350 | 50,225 | |
Aug 30 2016 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | EVP, Chief Medical ... | Sell | S | 95.06 | 15,000 | 1,425,924 | 113,878 | 128.9 K to 113.9 K (-11.64 %) |
Aug 30 2016 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | EVP, Chief Medical ... | Buy | M | 26.49 | 15,000 | 397,350 | 128,878 | 113.9 K to 128.9 K (+13.17 %) |
Aug 17 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.54 | 41,666 | 730,822 | 125,002 | |
Aug 17 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 91.49 | 41,666 | 3,811,868 | 378,584 | 420.3 K to 378.6 K (-9.91 %) |
Aug 17 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.54 | 41,666 | 730,822 | 420,250 | 378.6 K to 420.3 K (+11.01 %) |
Aug 17 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.54 | 41,666 | 730,822 | 125,002 | |
Aug 17 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 91.49 | 41,666 | 3,811,868 | 378,584 | 420.3 K to 378.6 K (-9.91 %) |
Aug 17 2016 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.54 | 41,666 | 730,822 | 420,250 | 378.6 K to 420.3 K (+11.01 %) |
Aug 03 2016 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 99.33 | 4,000 | 397,320 | 42,944 | 46.9 K to 42.9 K (-8.52 %) |
Aug 03 2016 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 100.00 | 2,167 | 216,700 | 71,158 | 73.3 K to 71.2 K (-2.96 %) |
Aug 03 2016 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Sell | S | 100.00 | 287 | 28,700 | 14,260 | 14.5 K to 14.3 K (-1.97 %) |
Jul 28 2016 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Option Exercise | M | 17.33 | 1,100 | 19,063 | 15,000 | |
Jul 28 2016 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Sell | S | 95.39 | 1,100 | 104,927 | 13,860 | 15 K to 13.9 K (-7.35 %) |
Jul 28 2016 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Buy | M | 17.33 | 1,100 | 19,063 | 14,960 | 13.9 K to 15 K (+7.94 %) |
Jul 26 2016 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Option Exercise | M | 17.33 | 6,400 | 110,912 | 16,100 |